Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer

Published:2015 Issue:3 Volume:18 Page:271
ISSN:1738-6756
Container-title:Journal of Breast Cancer
language:en
Short-container-title:J Breast Cancer

Author:

Kim Hyun-Ah¹,Seong Min-Ki¹,Kim Eun-kyu²,Kang Eunyoung²,Park Seho³,Hur Min Hee⁴,Song Byung Joo⁵,Noh Woo Chul¹,

Affiliation:

1. Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.

2. Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.

3. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

4. Department of Surgery, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea.

5. Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.

Publisher

Korean Breast Cancer Society

Subject

Cancer Research,Oncology

Link

https://synapse.koreamed.org/pdf/10.4048/jbc.2015.18.3.271

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients;npj Breast Cancer;2023-09-30

2. Geriatric Early-Stage Triple-Negative Breast Cancer Patients in Low-risk Population: Omitting Chemotherapy Based on Nomogram;Clinical Breast Cancer;2022-12

3. A careful reassessment of anthracycline use in curable breast cancer;npj Breast Cancer;2021-10-08

4. The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis;Journal of Cancer;2021

5. Adjuvant chemotherapy for small, lymph node–negative, triple‐negative breast cancer: A single‐center study and a meta‐analysis of the published literature;Cancer;2020-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3